These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 17696802

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
    Bottino D, Penland RC, stamps A, Traebert M, Dumotier B, Georgiva A, Helmlinger G, Lett GS.
    Prog Biophys Mol Biol; 2006; 90(1-3):414-43. PubMed ID: 16321428
    [Abstract] [Full Text] [Related]

  • 3. Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety.
    Gintant GA, Su Z, Martin RL, Cox BF.
    Toxicol Pathol; 2006; 34(1):81-90. PubMed ID: 16507548
    [Abstract] [Full Text] [Related]

  • 4. Models for profiling the potential QT prolongation risk of drugs.
    Muzikant AL, Penland RC.
    Curr Opin Drug Discov Devel; 2002 Jan; 5(1):127-35. PubMed ID: 11865666
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Torsades de pointes liability inter-model comparisons: the experience of the QT PRODACT initiative.
    Hashimoto K.
    Pharmacol Ther; 2008 Aug; 119(2):195-8. PubMed ID: 18486227
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The impact of drug-induced QT interval prolongation on drug discovery and development.
    Fermini B, Fossa AA.
    Nat Rev Drug Discov; 2003 Jun; 2(6):439-47. PubMed ID: 12776219
    [Abstract] [Full Text] [Related]

  • 9. Supplemental studies for cardiovascular risk assessment in safety pharmacology: a critical overview.
    Picard S, Goineau S, Guillaume P, Henry J, Hanouz JL, Rouet R.
    Cardiovasc Toxicol; 2011 Dec; 11(4):285-307. PubMed ID: 21805209
    [Abstract] [Full Text] [Related]

  • 10. Use of in vitro methods to predict QT prolongation.
    Hammond TG, Pollard CE.
    Toxicol Appl Pharmacol; 2005 Sep 01; 207(2 Suppl):446-50. PubMed ID: 16023163
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Guidelines for treating cardiac manifestations of organophosphates poisoning with special emphasis on long QT and Torsades De Pointes.
    Bar-Meir E, Schein O, Eisenkraft A, Rubinshtein R, Grubstein A, Militianu A, Glikson M, CBRN Medical Branch, Medical Corps, Israel Defense Forces.
    Crit Rev Toxicol; 2007 Mar 01; 37(3):279-85. PubMed ID: 17453935
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. QT prolongation in guinea pigs for preliminary screening of torsadogenicity of drugs and drug-candidates. II.
    Testai L, Breschi MC, Martinotti E, Calderone V.
    J Appl Toxicol; 2007 Mar 01; 27(3):270-5. PubMed ID: 17265420
    [Abstract] [Full Text] [Related]

  • 19. Drug-induced QT prolongation and proarrhythmia: an inevitable link?
    Ahmad K, Dorian P.
    Europace; 2007 Sep 01; 9 Suppl 4():iv16-22. PubMed ID: 17766320
    [Abstract] [Full Text] [Related]

  • 20. Relevance of in vitro SCREENIT results for drug-induced QT interval prolongation in vivo: a database review and analysis.
    Dumotier BM, Deurinck M, Yang Y, Traebert M, Suter W.
    Pharmacol Ther; 2008 Aug 01; 119(2):152-9. PubMed ID: 18462801
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.